Preclinical News and Research

RSS
Amakem receives €18m in Series A round of funding

Amakem receives €18m in Series A round of funding

NOXXON to commence NOX-H94 Phase I trial in anemia of chronic disease

NOXXON to commence NOX-H94 Phase I trial in anemia of chronic disease

Cancer cells with specific genetic defect extra susceptible to therapy that damages DNA

Cancer cells with specific genetic defect extra susceptible to therapy that damages DNA

Mesoblast receives EMA clearance to initiate Revascor Phase 2 trial for heart attacks

Mesoblast receives EMA clearance to initiate Revascor Phase 2 trial for heart attacks

Australia’s Mesoblast receives nod to start first European trial of allogeneic stem cell treatment for heart attacks

Australia’s Mesoblast receives nod to start first European trial of allogeneic stem cell treatment for heart attacks

Key international experts to attend major European bone congress in Bourse, France

Key international experts to attend major European bone congress in Bourse, France

Mayo Clinic and IC-MedTech enter collaborative research agreement with Summa Health System

Mayo Clinic and IC-MedTech enter collaborative research agreement with Summa Health System

UTHealth Phase I trial: Bone marrow stem cell therapy feasible, safe for acute stroke patients

UTHealth Phase I trial: Bone marrow stem cell therapy feasible, safe for acute stroke patients

SAIC awards Selecta a subcontract to develop synthetic nanoparticle vaccine for malaria

SAIC awards Selecta a subcontract to develop synthetic nanoparticle vaccine for malaria

Enrollment commences in Adamis' APC-100 Phase 1/2a clinical prostate study

Enrollment commences in Adamis' APC-100 Phase 1/2a clinical prostate study

Adimab initiates independent collaborations with Biogen Idec and Novo Nordisk

Adimab initiates independent collaborations with Biogen Idec and Novo Nordisk

AMT total net loss decreases 7% to € 8.7 million for first half year of 2011

AMT total net loss decreases 7% to € 8.7 million for first half year of 2011

USPTO issues Notice of Allowance for Cortex AMPAKINE molecules to treat respiratory depression

USPTO issues Notice of Allowance for Cortex AMPAKINE molecules to treat respiratory depression

BioLineRx second quarter net loss decreases to NIS 16.4 million

BioLineRx second quarter net loss decreases to NIS 16.4 million

KalVista raises £8 million in series A round of funding

KalVista raises £8 million in series A round of funding

Spinifex secures AU$6.25 million in expanded Series B funding

Spinifex secures AU$6.25 million in expanded Series B funding

Symphogen initiates Sym004 Phase 2 trial in squamous cell carcinoma of head and neck cancer

Symphogen initiates Sym004 Phase 2 trial in squamous cell carcinoma of head and neck cancer

Stem cells of oral mucosa stay young, says Tel Aviv University researcher

Stem cells of oral mucosa stay young, says Tel Aviv University researcher

New report: Molecular imaging market to reach $6 billion by 2015

New report: Molecular imaging market to reach $6 billion by 2015

Risk of Parkinson's disease increases with traumatic brain injury and exposure to pesticide paraquat

Risk of Parkinson's disease increases with traumatic brain injury and exposure to pesticide paraquat

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.